The University of Manchester
The University of Manchester is the largest University in the UK by student umbers, one of the largest in terms of grant income, and in the top 5 in terms of the recent RAE rating. It has an ambitious agenda to increase its quality further, with the aim of being one of the top 25 Universities in the world by 2020. To this end, it has invested substantially in research and teaching, particularly in interdisciplinary areas. Historically, no fewer than 25 former staff and students have gone on to become Nobel Prize winners. There are more than fifty specialist research centres and groups at the University, each undertaking pioneering research into areas ranging from hypertension, neurodegeneration and diabetes to artificial intelligence and aeronautics. The Faculty of Biology, Medicine and Health within the University is integral to the structure of the MCCIR.
+/- The Faculty of Biology, Medicine and Health
Athena SWAN Awards
The MCCIR currently holds the Athena SWAN Bronze Award through the Faculty of Medical and Human Sciences and the Silver Award through the Faculty of Life Sciences.
Read more about the Athena SWAN awards
Maarten Kraan, Head of the Respiratory, Inflammation and Autoimmunity Medicines Unit at AstraZeneca said:
“By working together we hope to enable a better understanding of inflammatory processes and ultimately achieve faster delivery of new medicines to patients.”
Dr Menelas Pangalos, Executive Vice-President Innovative Medicines and Early Development at AstraZeneca adds:
“Inflammatory processes underpin many of our priority areas of research and this is a ground-breaking collaboration. The creation of the new centre is indicative of a new era of pre-competitive sharing within the pharmaceutical sector and with academic scientists, to bring our learning together to ensure the faster delivery of effective medicines to patients.”
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. Respiratory, Inflammation, Autoimmunity is one AstraZeneca’s core areas, along with Oncology, and Cardiovascular and Metabolic Diseases, where it will focus its efforts to develop new therapies of the future. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information please visit: AstraZeneca
Talking about the MCCIR Dave Allen, Senior Vice-President of Respiratory Research at GlaxoSmithKline says:
“The translation of basic research discoveries into new medicines is challenging, but we believe we improve our chances of success through collaborative science. The MCCIR will embody this approach, and I am delighted that GSK has been able to contribute to its development and will continue to be an active partner.”
GSK is one of the world’s leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
For further information please visit: GlaxoSmithKline